Gregory L. Beatty

15.8k total citations · 8 hit papers
102 papers, 11.6k citations indexed

About

Gregory L. Beatty is a scholar working on Oncology, Immunology and Cancer Research. According to data from OpenAlex, Gregory L. Beatty has authored 102 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 59 papers in Immunology and 13 papers in Cancer Research. Recurrent topics in Gregory L. Beatty's work include Cancer Immunotherapy and Biomarkers (47 papers), Pancreatic and Hepatic Oncology Research (36 papers) and Immune cells in cancer (28 papers). Gregory L. Beatty is often cited by papers focused on Cancer Immunotherapy and Biomarkers (47 papers), Pancreatic and Hepatic Oncology Research (36 papers) and Immune cells in cancer (28 papers). Gregory L. Beatty collaborates with scholars based in United States, Slovakia and Germany. Gregory L. Beatty's co-authors include Whitney L. Gladney, Robert H. Vonderheide, Andrew D. Rhim, Ben Z. Stanger, Drew A. Torigian, Peter J. O’Dwyer, Yvonne Paterson, Kristen B. Long, Carl H. June and Bruce L. Levine and has published in prestigious journals such as Science, Cell and Nature Communications.

In The Last Decade

Gregory L. Beatty

99 papers receiving 11.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EMT and Dissemination Precede Pancreatic Tumor Formation

2012 1.6k citations Gregory L. Beatty, Robert H. Vonderheide et al. profile →
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

2011 1.3k citations Gregory L. Beatty, E. Gabriela Chiorean et al. profile →
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

2014 827 citations Gregory L. Beatty, Whitney L. Gladney Clinical Cancer Research profile →
Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer

2012 727 citations Gregory L. Beatty, Carolyn E. Clark et al. profile →
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

2013 693 citations Gregory L. Beatty, Andrew R. Haas et al. Cancer Immunology Research profile →
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

2013 476 citations Marcela V. Maus, Andrew R. Haas et al. Cancer Immunology Research profile →
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

2018 379 citations Gregory L. Beatty, Mark H. O’Hara et al. Gastroenterology profile →
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance

2022 236 citations Gregory L. Beatty et al. profile →

Peers

Countries citing papers authored by Gregory L. Beatty

Since Specialization

Citations

This map shows the geographic impact of Gregory L. Beatty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory L. Beatty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory L. Beatty more than expected).

Fields of papers citing papers by Gregory L. Beatty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory L. Beatty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory L. Beatty. The network helps show where Gregory L. Beatty may publish in the future.

Co-authorship network of co-authors of Gregory L. Beatty

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory L. Beatty. A scholar is included among the top collaborators of Gregory L. Beatty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory L. Beatty. Gregory L. Beatty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma 2025 ·Cancer Immunology Research ·Meredith L. Stone, (unknown), (unknown), (unknown), (unknown), Kathleen Graham, (unknown), (unknown), Shaun O’Brien, Gregory L. Beatty	0
2	Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma 2024 ·Gastroenterology ·Max M. Wattenberg, (unknown), Ignacio Garrido‐Laguna, (unknown), (unknown), (unknown), Jesse Lee, Kajsa E. Affolter, Sean J. Mulvihill, Muhammad Shaalan Beg, Andrea Wang‐Gillam, James L. Wade, Katherine A. Guthrie, E. Gabriela Chiorean, Syed A. Ahmad, Andrew M. Lowy, Philip Agop Philip, Davendra Sohal, Gregory L. Beatty	11
3	Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer 2024 ·Cancer Research ·Jonathan Sussman, (unknown), Samantha B. Kemp, Daniel Traum, Takeshi Katsuda, Benjamin Kahn, (unknown), Il‐Kyu Kim, (unknown), (unknown), Gregory L. Beatty, Klaus H. Kaestner, Amber L. Simpson, Ben Z. Stanger	8
4	CD4 effector T cell expansion to identify objective responses to the CD40 agonist mitazalimab in combination with modified FOLFIRINOX (mFFX) as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC) in the OPTIMIZE-1 study. 2024 ·Journal of Clinical Oncology ·Max M. Wattenberg, (unknown), Yago Pico de Coaña, (unknown), Sumeet Ambarkhane, Peter Ellmark, Gregory L. Beatty	0
5	Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer 2024 ·Carcinogenesis ·Gregory L. Beatty, Elizabeth M. Jaffee	2
6	Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice 2023 ·Nature Communications ·Stacy K. Thomas, Max M. Wattenberg, (unknown), Mark Uhlik, (unknown), (unknown), (unknown), Meredith L. Stone, (unknown), (unknown), Devora Delman, Michael Chisamore, (unknown), Nandita Bose, Gregory L. Beatty	20
7	Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration 2023 ·Clinical Cancer Research ·Gregory L. Beatty, (unknown), (unknown), Mingen Liu, Joey H. Li, (unknown), Jae W. Lee, (unknown), (unknown), Eugene P. Kennedy, Andrea Wang‐Gillam, Gabriela R. Rossi, Ignacio Garrido‐Laguna	10
8	A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy. 2023 ·Journal of Clinical Oncology ·Mark H. O’Hara, Max M. Wattenberg, Ignacio Garrido‐Laguna, Eileen M. O’Reilly, Michael Yellin, Tibor Keler, Michele Gargano, (unknown), (unknown), Nandita Bose, J. L. Mesías Iglesias, Gregory L. Beatty	1
9	Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis 2020 ·The Journal of Experimental Medicine ·Jeffrey H. Lin, Austin P. Huffman, Max M. Wattenberg, David M. Walter, Erica L. Carpenter, David M. Feldser, Gregory L. Beatty, Emma E. Furth, Robert H. Vonderheide	127
10	A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma 2020 ·Molecular Cancer Therapeutics ·Kim A. Reiss, Max M. Wattenberg, Nevena Damjanov, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Thomas B. Karasic, Emma E. Furth, Erica L. Carpenter, Andrzej P. Wojcieszynski, Robert H. Vonderheide, Gregory L. Beatty, Edgar Ben‐Josef	11
11	IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma 2017 ·Molecular Cancer Therapeutics ·Kristen B. Long, Graham M. Tooker, (unknown), (unknown), Jae W. Lee, Xiaoqing Pan, Gregory L. Beatty	89
12	IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma 2016 ·Cancer Discovery ·Kristen B. Long, Whitney L. Gladney, Graham M. Tooker, Kathleen Graham, Joseph A. Fraietta, Gregory L. Beatty	190
13	Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma 2016 ·Clinical Cancer Research ·Anusha Kalbasi, Chad A. Komar, Graham M. Tooker, Mingen Liu, Jae W. Lee, Whitney L. Gladney, Edgar Ben‐Josef, Gregory L. Beatty	248
14	Immune Escape Mechanisms as a Guide for Cancer Immunotherapy breakdown → 2014 ·Clinical Cancer Research ·Gregory L. Beatty, Whitney L. Gladney	827
15	A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma 2013 ·Clinical Cancer Research ·Gregory L. Beatty, Drew A. Torigian, E. Gabriela Chiorean, Babak Saboury, Alex Brothers, Abass Alavi, Andrea B. Troxel, Weijing Sun, Ursina Teitelbaum, Robert H. Vonderheide, Peter J. O’Dwyer	364
16	Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies breakdown → 2013 ·Cancer Immunology Research ·Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus, Drew A. Torigian, Michael C. Soulen, Gabriela Plesa, Anne Chew, Yangbing Zhao, Bruce L. Levine, Steven Μ. Albelda, Michael Kalos, Carl H. June	693
17	Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation 2009 ·Clinical Cancer Research ·Gregory L. Beatty, Jasmine S. Smith, Ran Reshef, Kunal P. Patel, Theresa A. Colligon, Barbara A. Vance, Noelle V. Frey, F. Brad Johnson, David L. Porter, Robert H. Vonderheide	36
18	Telomerase-Specific T-Cell Immunity in Breast Cancer: Effect of Vaccination on Tumor Immunosurveillance 2007 ·Cancer Research ·Susan M. Domchek, Adri Recio, Rosemarie Mick, Carolyn E. Clark, Erica L. Carpenter, Kevin R. Fox, Angela DeMichele, Lynn M. Schuchter, Michael S. Leibowitz, (unknown), Barbara A. Vance, Gregory L. Beatty, Elizabeth Veloso, Michael D. Feldman, Robert H. Vonderheide	75
19	IFN-γ-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-γ 2001 ·The Journal of Immunology ·Gregory L. Beatty, Yvonne Paterson	161
20	IFN-γ Can Promote Tumor Evasion of the Immune System In Vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen 2000 ·The Journal of Immunology ·Gregory L. Beatty, Yvonne Paterson	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact